The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture. As the formulation and manufacturing complexities have increased, competitive pressure to reduce development time and costs has escalated and the requirements for market access have grown more elaborate. In silico modeling, both in early development and across the product lifecycle, can streamline drug development and reduce the risks associated with trial-and-error experimental methods. This white paper outlines a framework for the implementation of in silico methods across all phases of development. Download now to learn more.
Please check the highlighted fields and try again.
Please fill out the information below. If you are already registered, login and this information will be filled out for you.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.
Please enter the phone number you would like to be contacted at.